Is Xiaflex (collagenase clostridium histolyticum) injection therapy medically necessary and considered standard of care for a male patient with stable Peyronie's disease, a palpable plaque, and curvature deformity, who has previously received injections and has intact erectile function?

Medical Necessity Determination for Xiaflex Continuation Therapy

Direct Answer to Medical Necessity

This patient does NOT meet medical necessity criteria for continuation of Xiaflex therapy because they have already received 8 total injections (4 injections prior to plan enrollment + 4 injections under current plan), which represents the maximum FDA-approved treatment course, and continuation beyond 8 total injections is neither FDA-approved nor supported by clinical evidence. 1, 2

---

Detailed Analysis of Medical Necessity Criteria

Initial Authorization Criteria Assessment

The patient did meet all initial authorization criteria at treatment onset: 1, 2

• Stable disease confirmed: Disease stable for ≥3 months without clinical changes 3
• Palpable plaque present: Documented on physical examination 1, 4
• Curvature within range: Deformity between 30° and 90° (FDA-approved indication range) 1, 4
• Intact erectile function: Maintained with or without medication 1, 2
• Age requirement met: Patient ≥18 years old 1

Critical Failure Point: Maximum Injection Limit Exceeded

The patient has received 8 total injections, which is the absolute maximum allowed per FDA approval and clinical guidelines: 1, 2

• Prior to plan enrollment: 4 injections (2 complete treatment cycles) 1
• Under current plan: 4 injections on the dates specified 1
• Total cumulative injections: 8 1, 2

The FDA-approved protocol explicitly limits treatment to a maximum of 8 injection procedures over 4 treatment cycles (approximately 24 weeks), and the safety of more than one treatment course has not been established. 1, 2, 4

Continuation Criteria Analysis

The plan's continuation criterion #3 states: "The patient has received less than 8 injections total, including any injections received for any previous treatment" - This criterion is NOT MET. 1

---

Standard of Care Assessment

Evidence-Based Treatment Guidelines

Xiaflex (collagenase clostridium histolyticum) is the only FDA-approved non-surgical therapy for stable Peyronie's disease and represents standard of care for appropriate candidates, but only within the approved 8-injection limit. 1, 2, 4

Guideline Support for Initial Treatment

• American Urological Association (2015): Provides moderate recommendation (Evidence Strength Grade B) for intralesional collagenase clostridium histolyticum combined with modeling for patients with stable Peyronie's disease with curvature between 30° and 90° 1, 2
• European Association of Urology (2025): Recommends CCH for stable disease with appropriate curvature range and intact erectile function 3, 2

Treatment Protocol Standards

The approved protocol consists of: 1, 2, 4

• Maximum 4 treatment cycles (each cycle = 6 weeks apart) 1, 2
• 2 injections per cycle (0.58 mg per injection, administered 24-72 hours apart) 1, 4
• Total maximum: 8 injections over approximately 24 weeks 1, 2, 4
• Mandatory modeling exercises performed by clinician and patient after each injection cycle 1, 2

Expected Clinical Outcomes

The IMPRESS I and II trials (the definitive phase 3 studies establishing FDA approval) demonstrated: 1, 4

• Mean curvature reduction of 17° with CCH versus 9.3° with placebo at one-year follow-up 1, 4
• Improvement in patient-reported bother and sexual function 1, 4
• Most adverse events were mild to moderate (84.2% of patients experienced at least one adverse event) 1, 4

---

Safety Considerations for Treatment Beyond 8 Injections

Lack of Safety Data

The safety and efficacy of administering more than 8 total injections (more than one complete treatment course) has NOT been established in clinical trials or post-marketing surveillance. 1, 2

Known Adverse Events Within Approved Protocol

Even within the approved 8-injection limit, patients face risks including: 1, 5, 4

• Common: Penile ecchymosis, swelling, pain (most mild-moderate) 1, 4
• Serious but rare (<1%): Corporal rupture, penile hematoma 1, 4
• Rare complications: Lateral herniation of tunica albuginea 5

Rationale for 8-Injection Limit

The 8-injection maximum exists because: 1, 2, 4

• Clinical trials only evaluated safety and efficacy through 8 injections 4
• Collagenase enzymatically degrades collagen in the tunica albuginea; excessive degradation increases risk of structural complications 5, 4
• If curvature decreases to <15° during treatment, subsequent cycles should not be administered 1

---

Alternative Management Options

If Residual Curvature Remains Problematic

For patients who complete 8 injections but have persistent curvature compromising sexual function, the appropriate next steps are: 2

1. Observation: If curvature is mild and not functionally limiting 2
2. Penile traction therapy: Non-invasive option requiring 2-8 hours daily use 3, 2
3. Surgical intervention: For patients with stable disease ≥3-6 months who have failed conservative therapy 3, 2
   • Tunical plication (for curvature without ED): >90% curvature improvement 2
   • Tunical lengthening with grafting (for severe curvature >60° or complex deformity): 25-100% improvement 2
   • Penile prosthesis (for concurrent ED): >80% curvature improvement 2

---

Clinical Pitfalls and Considerations

Common Errors in Xiaflex Administration

• Do NOT administer CCH beyond 8 total injections: No safety data exists for retreatment 1, 2
• Do NOT use CCH for pain management: CCH treats curvature only, not pain or erectile dysfunction 2, 6
• Do NOT administer during active disease phase: CCH is only indicated for stable disease 1, 2
• Do NOT continue if curvature decreases to <15°: Further treatment not indicated 1

Documentation Requirements

For any Xiaflex treatment, documentation must include: 1, 2

• Confirmation of stable disease (no changes for ≥3 months) 3, 1
• Objective measurement of penile curvature using goniometer or protractor during artificial erection 1, 7
• Palpable plaque confirmation on physical examination 1, 4
• Assessment of erectile function status 1, 2
• Cumulative injection count from all previous treatments 1

---

Final Determination

Question 1: Is the treatment plan medically necessary?

No, continuation of Xiaflex therapy is NOT medically necessary because the patient has already received the maximum FDA-approved and evidence-supported treatment course of 8 total injections. 1, 2 The plan's continuation criterion #3 explicitly requires that the patient has received less than 8 total injections, which is not met. 1 Administering additional injections would constitute off-label use without supporting safety or efficacy data and would expose the patient to unknown risks. 1, 2

Question 2: Is the treatment plan standard of care or experimental/investigational?

Xiaflex therapy within the approved 8-injection protocol is standard of care and FDA-approved for stable Peyronie's disease with appropriate curvature range. 1, 2, 4 However, administering more than 8 total injections (retreatment beyond one complete treatment course) is experimental/investigational, as the safety of more than one treatment course has not been established in clinical trials. 1, 2 The American Urological Association and European Association of Urology guidelines only support CCH use within the FDA-approved protocol parameters. 3, 1, 2

If the patient has persistent functionally limiting curvature after completing 8 injections, the evidence-based next step is surgical consultation, not additional Xiaflex injections. 3, 2